In recent years, a notably heterogeneous malignant tumor, squamous cell carcinoma of the head and neck (HNSCC), has received increasing attention, with no significant improvement in its survival rate. The rapid increase in the number of prognostic models associated with HNSCC has been observed due to its accuracy, which offers crucial clinical benefits. The 10 genes were selected from 222 human genes associated with the basement membrane in the analysis of this article. The gene pool was narrowed through different classifications and intersections, followed by univariate Cox regression analysis. Genes with statistical significance underwent further Least Absolute Shrinkage and Selection Operator (LASSO) regression analysis, resulting in the final selection of 10 genes. The data and images extracted from the Human Protein Atlas database were utilized to confirm the differential expression of the corresponding genes. Multivariate Cox regression analysis was employed to develop a nomogram, and the nomogram was assessed by additional decision curve analysis (DCA). The Gene Expression Omnibus validation set was used to validate the established model. Finally, between the high- and low-risk score groups, Gene Set Enrichment Analysis, immune correlation analysis, and drug sensitivity analysis were conducted in this paper. ITGA5, SPOCK1, EVA1C, TINAGL1, LAMB4, ADAMTS1, EGFL6, GPC2, BGN, and ITGA2B were successfully developed as basement membrane-associated risk models. The time-dependent receiver operating characteristic (timeROC) curve illustrated that the risk score prediction accuracy outperformed indicators, which were commonly adopted in clinical practice, consisting of age, stage, gender, T-staging, and N-staging. The 3-year risk score timeROC area under the curve value was 0.679. This model demonstrates a reliable ability to assess the prognosis of HNSCC patients. In addition, the specific potential biomarkers associated with the basement membrane were explored in this research.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/MD.0000000000041316 | DOI Listing |
J Clin Invest
January 2025
Center for Inherited Myology Research, Virginia Commonwealth University, Richmond, United States of America.
Background: Myotonic dystrophy type 1 (DM1) is a multisystemic, CTG repeat expansion disorder characterized by a slow, progressive decline in skeletal muscle function. A biomarker correlating RNA mis-splicing, the core pathogenic disease mechanism, and muscle performance is crucial for assessing response to disease-modifying interventions. We evaluated the Myotonic Dystrophy Splice Index (SI), a composite RNA splicing biomarker incorporating 22 disease-specific events, as a potential biomarker of DM1 muscle weakness.
View Article and Find Full Text PDFCancer Epidemiol Biomarkers Prev
January 2025
University of Kentucky, Lexington, KY, United States.
Background: Kentucky is within the top five leading states for breast mortality nationwide. This study investigates the association between neighborhood socioeconomic disadvantage and breast cancer outcomes, including surgical treatment, radiation therapy, chemotherapy, and survival, and how associations vary by race and ethnicity in Kentucky.
Methods: We conducted a retrospective cohort analysis using data from the Kentucky Cancer Registry (KCR) for breast cancer patients diagnosed between 2010 and 2017, with follow-up through December 31, 2022.
Cancer Epidemiol Biomarkers Prev
January 2025
A.C. Camargo Cancer Center, São Paulo, Brazil.
Background: Oropharyngeal cancer (OPC) incidence is rising globally, predominantly in high-income countries due to human papillomavirus (HPV) infection. However, further data on OPC incidence in Brazil is needed. The aim of this study was to estimate the incidence, trends, and predictions of OPC in Brazilian population-based cancer registries (PBCRs) by period, sex, and topography.
View Article and Find Full Text PDFJAMA Netw Open
January 2025
Department of Global Health, School of Public Health, Boston University, Boston, Massachusetts.
Importance: Semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, was approved for weight management in individuals with obesity in June 2021. There is limited evidence on factors associated with uptake among individuals in this subgroup without diabetes.
Objective: To explore factors associated with semaglutide initiation among a population of commercially insured individuals with obesity but no diagnosed diabetes.
JAMA Netw Open
January 2025
Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Importance: Secondary lymphedema is a common, harmful side effect of breast cancer treatment. Robust risk models that are externally validated are needed to facilitate clinical translation. A published risk model used 5 accessible clinical factors to predict the development of breast cancer-related lymphedema; this model included a patient's mammographic breast density as a novel predictive factor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!